www.renalandurologynews.com Open in urlscan Pro
2606:4700::6812:e1c  Public Scan

Form analysis
4 forms found in the DOM

https://www.renalandurologynews.com/

<form class="search focus-label" id="mobile-search" aria-hidden="true" action="https://www.renalandurologynews.com/" aria-expanded="false">
  <input class="searchinput predictive-search" id="q" type="text" value="" name="s">
  <label class="searchformlabel " id="q-label" for="q"> Search... </label>
  <button class="submit" type="submit">
    <span class="searchicon">
      <svg role="presentation" class="icon icon--search" aria-label="search">
        <use xlink:href="https://www.renalandurologynews.com/wp-content/themes/haymarket/assets/svg/src.svg?ver=1628100186#search"></use>
      </svg> </span>
    <span class="screen-reader-text">Submit</span>
  </button>
</form>

<form class="HMIRegistration__form" novalidate="">
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="email" id="root_subscriber_email" label="email" placeholder="*E-mail Address" value="">
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control "><select class="HMIRegistration__select">
          <option value="">*Select a Country</option>
          <option value="AF">Afghanistan</option>
          <option value="AL">Albania</option>
          <option value="DZ">Algeria</option>
          <option value="AS">American Samoa</option>
          <option value="AD">Andorra</option>
          <option value="AO">Angola</option>
          <option value="AI">Anguilla</option>
          <option value="AQ">Antarctica</option>
          <option value="AG">Antigua and Barbuda</option>
          <option value="AR">Argentina</option>
          <option value="AM">Armenia</option>
          <option value="AW">Aruba</option>
          <option value="AU">Australia</option>
          <option value="AT">Austria</option>
          <option value="AZ">Azerbaijan</option>
          <option value="BS">Bahamas</option>
          <option value="BH">Bahrain</option>
          <option value="BD">Bangladesh</option>
          <option value="BB">Barbados</option>
          <option value="BY">Belarus</option>
          <option value="BE">Belgium</option>
          <option value="BZ">Belize</option>
          <option value="BJ">Benin</option>
          <option value="BM">Bermuda</option>
          <option value="BT">Bhutan</option>
          <option value="BO">Bolivia</option>
          <option value="BA">Bosnia and Herzegovina</option>
          <option value="BW">Botswana</option>
          <option value="BV">Bouvet Island</option>
          <option value="BR">Brazil</option>
          <option value="IO">British Indian Ocean Territory</option>
          <option value="BN">Brunei Darussalam</option>
          <option value="BG">Bulgaria</option>
          <option value="BF">Burkina Faso</option>
          <option value="BI">Burundi</option>
          <option value="KH">Cambodia</option>
          <option value="CM">Cameroon</option>
          <option value="CA">Canada</option>
          <option value="CV">Cape Verde</option>
          <option value="KY">Cayman Islands</option>
          <option value="CF">Central African Republic</option>
          <option value="TD">Chad</option>
          <option value="CL">Chile</option>
          <option value="CN">China</option>
          <option value="CX">Christmas Island</option>
          <option value="CC">Cocos (Keeling) Islands</option>
          <option value="CO">Colombia</option>
          <option value="KM">Comoros</option>
          <option value="CG">Congo</option>
          <option value="CD">Congo (DRC)</option>
          <option value="CK">Cook Islands</option>
          <option value="CR">Costa Rica</option>
          <option value="HR">Croatia</option>
          <option value="CU">Cuba</option>
          <option value="CY">Cyprus</option>
          <option value="CZ">Czech Republic</option>
          <option value="CI">Côte D'Ivoire</option>
          <option value="DK">Denmark</option>
          <option value="DJ">Djibouti</option>
          <option value="DM">Dominica</option>
          <option value="DO">Dominican Republic</option>
          <option value="EC">Ecuador</option>
          <option value="EG">Egypt</option>
          <option value="SV">El Salvador</option>
          <option value="GQ">Equatorial Guinea</option>
          <option value="ER">Eritrea</option>
          <option value="EE">Estonia</option>
          <option value="ET">Ethiopia</option>
          <option value="FK">Falkland Islands (Malvinas)</option>
          <option value="FO">Faroe Islands</option>
          <option value="FJ">Fiji Islands</option>
          <option value="FI">Finland</option>
          <option value="FR">France</option>
          <option value="GF">French Guiana</option>
          <option value="PF">French Polynesia</option>
          <option value="TF">French Southern Territories</option>
          <option value="GA">Gabon</option>
          <option value="GM">Gambia</option>
          <option value="GE">Georgia</option>
          <option value="DE">Germany</option>
          <option value="GH">Ghana</option>
          <option value="GI">Gibraltar</option>
          <option value="GR">Greece</option>
          <option value="GL">Greenland</option>
          <option value="GD">Grenada</option>
          <option value="GP">Guadeloupe</option>
          <option value="GU">Guam</option>
          <option value="GT">Guatemala</option>
          <option value="GN">Guinea</option>
          <option value="GW">Guinea-Bissau</option>
          <option value="GY">Guyana</option>
          <option value="HT">Haiti</option>
          <option value="HM">Heard Island and Mcdonald Islands</option>
          <option value="HN">Honduras</option>
          <option value="HK">Hong Kong</option>
          <option value="HU">Hungary</option>
          <option value="IS">Iceland</option>
          <option value="IN">India</option>
          <option value="ID">Indonesia</option>
          <option value="IR">Iran</option>
          <option value="IQ">Iraq</option>
          <option value="IE">Ireland</option>
          <option value="IL">Israel</option>
          <option value="IT">Italy</option>
          <option value="JM">Jamaica</option>
          <option value="JP">Japan</option>
          <option value="JO">Jordan</option>
          <option value="KZ">Kazakhstan</option>
          <option value="KE">Kenya</option>
          <option value="KI">Kiribati</option>
          <option value="KR">Korea</option>
          <option value="KW">Kuwait</option>
          <option value="KG">Kyrgyzstan</option>
          <option value="LA">Laos</option>
          <option value="LV">Latvia</option>
          <option value="LB">Lebanon</option>
          <option value="LS">Lesotho</option>
          <option value="LR">Liberia</option>
          <option value="LY">Libya</option>
          <option value="LI">Liechtenstein</option>
          <option value="LT">Lithuania</option>
          <option value="LU">Luxembourg</option>
          <option value="MO">Macao</option>
          <option value="MK">Macedonia</option>
          <option value="MG">Madagascar</option>
          <option value="MW">Malawi</option>
          <option value="MY">Malaysia</option>
          <option value="MV">Maldives</option>
          <option value="ML">Mali</option>
          <option value="MT">Malta</option>
          <option value="MH">Marshall Islands</option>
          <option value="MQ">Martinique</option>
          <option value="MR">Mauritania</option>
          <option value="MU">Mauritius</option>
          <option value="YT">Mayotte</option>
          <option value="MX">Mexico</option>
          <option value="FM">Micronesia</option>
          <option value="MD">Moldova</option>
          <option value="MC">Monaco</option>
          <option value="MN">Mongolia</option>
          <option value="ME">Montenegro</option>
          <option value="MS">Montserrat</option>
          <option value="MA">Morocco</option>
          <option value="MZ">Mozambique</option>
          <option value="MM">Myanmar</option>
          <option value="NA">Namibia</option>
          <option value="NR">Nauru</option>
          <option value="NP">Nepal</option>
          <option value="NL">Netherlands</option>
          <option value="AN">Netherlands Antilles</option>
          <option value="NC">New Caledonia</option>
          <option value="NZ">New Zealand</option>
          <option value="NI">Nicaragua</option>
          <option value="NE">Niger</option>
          <option value="NG">Nigeria</option>
          <option value="NU">Niue</option>
          <option value="NF">Norfolk Island</option>
          <option value="KP">North Korea</option>
          <option value="MP">Northern Mariana Islands</option>
          <option value="NO">Norway</option>
          <option value="OM">Oman</option>
          <option value="PK">Pakistan</option>
          <option value="PW">Palau</option>
          <option value="PA">Panama</option>
          <option value="PG">Papua New Guinea</option>
          <option value="PY">Paraguay</option>
          <option value="PE">Peru</option>
          <option value="PH">Philippines</option>
          <option value="PN">Pitcairn</option>
          <option value="PL">Poland</option>
          <option value="PT">Portugal</option>
          <option value="PR">Puerto Rico</option>
          <option value="QA">Qatar</option>
          <option value="RE">Reunion</option>
          <option value="RO">Romania</option>
          <option value="RU">Russia</option>
          <option value="RW">Rwanda</option>
          <option value="SH">Saint Helena</option>
          <option value="KN">Saint Kitts and Nevis</option>
          <option value="LC">Saint Lucia</option>
          <option value="MF">Saint Martin</option>
          <option value="PM">Saint Pierre and Miquelon</option>
          <option value="VC">Saint Vincent and The Grenadines</option>
          <option value="SM">San Marino</option>
          <option value="ST">Sao Tome &amp; Principe</option>
          <option value="SA">Saudi Arabia</option>
          <option value="SN">Senegal</option>
          <option value="YU">Serbia and Montenegro</option>
          <option value="RS">Serbia-Montenegro</option>
          <option value="SC">Seychelles</option>
          <option value="SL">Sierra Leone</option>
          <option value="SG">Singapore</option>
          <option value="SK">Slovakia</option>
          <option value="SI">Slovenia</option>
          <option value="SB">Solomon Islands</option>
          <option value="SO">Somalia</option>
          <option value="ZA">South Africa</option>
          <option value="ES">Spain</option>
          <option value="LK">Sri Lanka</option>
          <option value="SD">Sudan</option>
          <option value="SR">Suriname</option>
          <option value="SJ">Svalbard and Jan Mayen</option>
          <option value="SZ">Swaziland</option>
          <option value="SE">Sweden</option>
          <option value="CH">Switzerland</option>
          <option value="SY">Syria</option>
          <option value="TW">Taiwan</option>
          <option value="TJ">Tajikistan</option>
          <option value="TZ">Tanzania</option>
          <option value="TH">Thailand</option>
          <option value="TP">Timor-Leste</option>
          <option value="TG">Togo</option>
          <option value="TK">Tokelau</option>
          <option value="TO">Tonga</option>
          <option value="TT">Trinidad and Tobago</option>
          <option value="TN">Tunisia</option>
          <option value="TR">Turkey</option>
          <option value="TM">Turkmenistan</option>
          <option value="TC">Turks and Caicos Islands</option>
          <option value="TV">Tuvalu</option>
          <option value="UG">Uganda</option>
          <option value="UA">Ukraine</option>
          <option value="AE">United Arab Emirates</option>
          <option value="UK">United Kingdom</option>
          <option value="US">United States</option>
          <option value="UY">Uruguay</option>
          <option value="UZ">Uzbekistan</option>
          <option value="VU">Vanuatu</option>
          <option value="VA">Vatican City</option>
          <option value="VE">Venezuela</option>
          <option value="VN">Viet Nam</option>
          <option value="VI">Virgin Islands</option>
          <option value="VG">Virgin Islands, British</option>
          <option value="WF">Wallis and Futuna</option>
          <option value="WS">Western Samoa</option>
          <option value="YE">Yemen</option>
          <option value="ZM">Zambia</option>
          <option value="ZW">Zimbabwe</option>
        </select>
        <div class="HMIRegistration__select--down-caret"><svg width="14 " height="12" class="widget-svg">
            <polygon class="down-caret" points="7 12, 14 0, 0 0"></polygon>
          </svg></div>
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control--checkbox ">
        <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite ismedical"><span class="HMIRegistration__sprite-border u-active"></span><span class="HMIRegistration__sprite-checkmark u-active"><svg width="15" height="15"
                class="widget-svg">
                <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
              </svg></span><span class="HMIRegistration__sprite-fill u-active"></span></span><span class="HMIRegistration__text u-active">Today’s Update</span></div>
      </div>
      <div class="HMIRegistration__form-control--checkbox ">
        <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite ismedical"><span class="HMIRegistration__sprite-border u-active"></span><span class="HMIRegistration__sprite-checkmark u-active"><svg width="15" height="15"
                class="widget-svg">
                <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
              </svg></span><span class="HMIRegistration__sprite-fill u-active"></span></span><span class="HMIRegistration__text u-active">Renal &amp; Urology News eTOC</span></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row HMIRegistration__opt-in-email" style="display: none;">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite"><span class="HMIRegistration__sprite-border "></span><span class="HMIRegistration__sprite-checkmark "><svg width="15" height="15" class="widget-svg">
              <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
            </svg></span><span class="HMIRegistration__sprite-fill "></span></span><span class="HMIRegistration__text ">I would like to receive relevant information via email from Renal and Urology News / Haymarket Medical Network.</span></div>
    </div>
  </div>
  <div class="HMIRegistration__row HMIRegistration__opt-in-email" style="display: none;">
    <div class="HMIRegistration__column u-col12">By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our
      <a href="/privacypolicy" target="_blank">privacy policy</a> and &nbsp;<a href="/termsandconditions" target="_blank">terms and conditions</a></div>
  </div><button class="HMIRegistration__submit" type="submit">Sign Up!</button>
  <div class="HMIRegistration__us_privacy-policy privacy__terms" id="newsletter-asset" style="display: block;"><a href="https://www.haymarketmediaus.com/haymarket-media-medical-privacy-policy/" target="_blank">Privacy Policy</a> &nbsp;|
    &nbsp;<a href="https://www.haymarketmediaus.com/haymarket-medical-business-terms-conditions/" target="_blank">Terms &amp; Conditions</a></div>
</form>

<form class="HMIRegistration__form ismedical" novalidate="">
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="email" id="root_email" label="email" placeholder="*E-mail Address" value="">
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="password" id="root_password" label="password" placeholder="*Password" value="">
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite"><span class="HMIRegistration__sprite-border "></span><span class="HMIRegistration__sprite-checkmark "><svg width="15" height="15" class="widget-svg">
              <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
            </svg></span><span class="HMIRegistration__sprite-fill "></span></span><span class="HMIRegistration__text ">Keep me signed in</span></div>
    </div>
  </div>
  <p class="HMIRegistration__text linkToForgetPword ismedical"><a href="#" class="HMIRegistration__link ismedical">Forgot your password?</a></p><button class="HMIRegistration__submit ismedical" type="submit">Login</button>
  <p class="HMIRegistration__text goToRegister ismedical"><a href="#" class="HMIRegistration__link ismedical">Do not have an account yet?<strong> Register</strong></a></p>
</form>

<form class="HMIRegistration__form ismedical" novalidate="">
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="email" id="root_email" label="email" placeholder="*E-mail Address" value="">
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="password" id="root_password" label="password" placeholder="*Password" value="">
        <div></div>
      </div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite"><span class="HMIRegistration__sprite-border "></span><span class="HMIRegistration__sprite-checkmark "><svg width="15" height="15" class="widget-svg">
              <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
            </svg></span><span class="HMIRegistration__sprite-fill "></span></span><span class="HMIRegistration__text ">Keep me signed in</span></div>
    </div>
  </div>
  <p class="HMIRegistration__text linkToForgetPword ismedical"><a href="#" class="HMIRegistration__link ismedical">Forgot your password?</a></p><button class="HMIRegistration__submit ismedical" type="submit">Login</button>
  <p class="HMIRegistration__text goToRegister ismedical"><a href="#" class="HMIRegistration__link ismedical">Do not have an account yet?<strong> Register</strong></a></p>
</form>

Text Content

Skip to navigation Skip to main content
Menu Close
Search... Submit
 * Prostate Cancer
 * ED
 * CKD
 * UrologyOpen Submenu
   * Urology Back
      * Urology News
      * Conference Coverage
     
      * Benign Prostatic Hyperplasia (BPH)
      * Bladder Cancer
      * Erectile Dysfunction
      * Hypogonadism
      * Kidney Cancer
     
      * Kidney Stones
      * Men’s Health
      * Overactive Bladder (OAB)
      * Premature Ejaculation
      * Prostate Cancer
     
      * Reproductive Medicine
      * Upper Tract Urothelial Carcinoma
      * Urinary Incontinence
      * Urinary Tract Infections (UTI)
 * NephrologyOpen Submenu
   * Nephrology Back
      * Nephrology
      * Conference Coverage
     
      * Acute Kidney Injury
      * Anemia
      * Contrast Nephropathy
      * Cardiovascular Disease (CVD)
      * Chronic Kidney Disease (CKD)
     
      * Diabetes
      * Diabetic Nephropathy
      * End-Stage Renal Disease
      * Hemodialysis
      * Hyperkalemia
      * Hyperphosphatemia
      * Hypertension
     
      * Hyperuricemia
      * Lupus Nephritis
      * Nutrition
      * Peritoneal Dialysis
      * Secondary Hyperparathyroidism
      * Transplantation
 * My PracticeOpen Submenu
   * My Practice Back
      * Commentary
      * Drug Information Database
      * Ethical Issues in Medicine
      * General Medicine
      * HIPAA Compliance
      * Legal Issues in Medicine
      * Practice Management
      * Product Guide
 * Web ExclusivesOpen Submenu
   * Web Exclusives Back
      * Expert Perspectives
      * Cartoons
      * Clinical Quiz
      * Drugs in the Pipeline
     
      * Medical Calculators
      * Medical Charts
      * Multimedia
      * Polls
      * Prostate Cancer Management Across America
 * Conferences
 * Resources

Toggle Search Menu
 * Headlines
 * Jobs
 * Commentary
 * Poll
 * Drugs
 * CME

Login Register
 * Submit

 * 
 * 
 * 

PROSTATE CANCER ADVISOR



Home » News » Urology » Prostate Cancer

Publish Date July 1, 2021


ACTIVE SURVEILLANCE FOR INTERMEDIATE-RISK PROSTATE CANCER LINKED WITH LOWER
SURVIVAL

Natasha Persaud

 * Share on Facebook
 * Share on Twitter
 * Share on LinkedIn
 * Share on Reddit
 * Print
 * Share by Email

Active surveillance for some patients with GG2 prostate cancer is still
reasonable to offer, according to Hiten D. Patel, MD, MPH, of Loyola University
Medical Center, who was not involved in this study.


Active surveillance (AS) should be cautiously offered to men with
intermediate-risk prostate cancer, investigators suggest.

Thenappan Chandrasekar, MD, and colleagues from Thomas Jefferson University in
Philadelphia, Pennsylvania, conducted the first population-level analysis of AS,
watchful waiting (WW), and active treatment (AT) for low-risk and
intermediate-risk prostate cancer. Using the Surveillance, Epidemiology, and End
Results (SEER) database 2010-2015, the investigators identified 166,244 men with
localized Grade Group (GG) 1 or 2 disease. They were able to distinguish
patients on WW versus AS using the recent SEER WW variable.





At 5 years, both cancer-specific (CSS) and overall survival (OS) appeared worse
for patients with GG2 and intermediate-risk prostate cancer receiving AS
compared with AT involving curative surgery or radiation therapy, Dr
Chandrasekar’s team reported in Urology. Among men with GG2, the 5-year CSS was
100% in the AT group compared with 99% in the AS group, and the 5-year OS was
94% vs 88%, respectively. The investigators further stratified 94,891 patients
by National Comprehensive Cancer Network (NCCN) favorable and unfavorable risk
categories. Among patients with favorable intermediate-risk disease, the 5-year
CSS was 100% vs 99% and the 5-year OS was 95% vs 91%, in the AT and AS groups,
respectively. Among men with unfavorable intermediate-risk disease, the 5-year
CSS was 100% vs 98% and the 5-year OS was 94% vs 88%, in the AT and AS groups,
respectively.





Today’s top picks on the Haymarket Medical Network
Ultrasound Detects Ulcerative Colitis Disease ActivityHaymarket MediaSeptember
1, 2021
Previous Treatment in Metastatic Melanoma May Cut Response to ACT TILHaymarket
MediaAugust 31, 2021
Apalutamide Prolongs Survival in mCSPC Regardless of Disease VolumeJody A.
CharnowJuly 14, 2021

--------------------------------------------------------------------------------

Continue Reading




In contrast, men with GG1 prostate cancer had similar survival outcomes whether
or not they received active treatment. Among the GG1 cohort, the 5-year CSS was
100% vs 100% and the 5-year OS was 95% vs 94%, in the AT vs AS group,
respectively. The WW group, which included older men with comorbidities (as well
as those not enrolled in AS or AT for any reason), had the worst survival
outcomes across all cohorts. 

“Our analysis of a real-world, population level dataset validates the findings
of smaller prospective cohorts suggesting that AS should be used cautiously in
patients with reasonable life expectancy diagnosed with GG2 or
[intermediate-risk prostate cancer],” Dr Chandrasekar’s team concluded. The
investigators encouraged continued research to determine which subgroups of
patients with intermediate-risk prostate cancer would benefit from AS.
Multiparametric magnetic resonance imaging, tissue-based genetic assays,
identification of germline mutations in DNA repair genes, and family history all
may improve risk stratification, they noted. 

In an interview, Hiten D. Patel, MD, MPH, of Loyola University Medical Center in
Maywood, Illinois, who was not involved in this study but has conducted research
in this area, observed, “I still believe AS for some GG2 patients is reasonable
to offer. Patients need to be informed upfront that AS for GG2 prostate cancer
cannot be equated with AS for GG1, so they are taking a calculated risk. With
shared decision-making, AS could still be in-line with a patient’s preferences,
such as quality of life.”

In previous studies (JAMA Oncol. 2018 and J Urol. 2018), Dr Patel and colleagues
showed that patients with GG2 prostate cancer in virtually all subsets have
higher rates of adverse pathologic findings at surgery compared with NCCN
low-risk patients. “Therefore, we would expect the same patients placed on AS
would have some marginal decrease in CSS,” Dr Patel said. In the current study,
the small 5-year differences in CSS between favorable and unfavorable disease
could be considered “reasonable trade-offs” by some advocates of AS for
intermediate-risk prostate cancer, he said.

According to Dr Patel, there may be a few clinical groups that are at lower risk
for adverse outcomes on AS, including patients with a single MRI-identified
prostate lesion that is biopsy-confirmed to be GG2, those with low-volume
disease and a negative MRI, and patients who have less than 5% of Gleason
pattern 4.

“There is still a lot of research needed in this area to set safe but useful
triggers for active treatment,” he noted. “Optimal data for localized prostate
cancer would require 10 to 15 years of follow-up.

“The real question for patients with GG2 prostate cancer considered for AS is
how durable the management strategy is. If thresholds are set such that all
patients cross over to active treatment within a few years, then perhaps the
limited benefit gained from the intervention-free period will outweigh the
additional costs and anxiety.”

Reference

Chandrasekar T, Bowler N, Schneider A, et al. Outcomes of active surveillance
for men with intermediate risk prostate cancer: a population-based analysis.
Urology. Published online June 27, 2021. doi:10.1016/j.urology.2021.05.068


TOPICS:

Men's Health Prostate Cancer


 * GET RENAL UROLOGY ADVISOR IN YOUR INBOX
   
   Sign up to get the latest renal and urology news in your inbox.
   
   *Select a CountryAfghanistanAlbaniaAlgeriaAmerican
   SamoaAndorraAngolaAnguillaAntarcticaAntigua and
   BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia
   and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean
   TerritoryBrunei DarussalamBulgariaBurkina
   FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African
   RepublicChadChileChinaChristmas IslandCocos (Keeling)
   IslandsColombiaComorosCongoCongo (DRC)Cook IslandsCosta
   RicaCroatiaCubaCyprusCzech RepublicCôte
   D'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl
   SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands
   (Malvinas)Faroe IslandsFiji IslandsFinlandFranceFrench GuianaFrench
   PolynesiaFrench Southern
   TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard
   Island and Mcdonald IslandsHondurasHong
   KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall
   IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands
   AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth
   KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPanamaPapua New
   GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto
   RicoQatarReunionRomaniaRussiaRwandaSaint HelenaSaint Kitts and NevisSaint
   LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and The GrenadinesSan
   MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbia and
   MontenegroSerbia-MontenegroSeychellesSierra
   LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri
   LankaSudanSurinameSvalbard and Jan
   MayenSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad
   and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos
   IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited
   StatesUruguayUzbekistanVanuatuVatican CityVenezuelaViet NamVirgin
   IslandsVirgin Islands, BritishWallis and FutunaWestern
   SamoaYemenZambiaZimbabwe
   
   
   Today’s Update
   Renal & Urology News eTOC
   I would like to receive relevant information via email from Renal and Urology
   News / Haymarket Medical Network.
   By registering you consent to the collection and use of your information to
   provide the products and services you have requested from us and as described
   in our privacy policy and  terms and conditions
   Sign Up!
   Privacy Policy  |  Terms & Conditions
   
   

 * 
 * 
 * Loading...
   
   Popular in Renal and Urology News
   
   Nomograms May Aid Patient Selection for 177Lu-PSMA Therapy in Metastatic
   Castration-Resistant Prostate Cancer Leah Lawrence 3 August 2021
   renalandurologynews.com The nomograms predicted overall and progression-free
   survival. mpMRI Misses Few Significant Prostate Cancers in Re-Biopsied Men
   Natasha Persaud 12 July 2021 renalandurologynews.com Study findings lend
   support to using mpMRI for prostate cancer detection. Characteristics of Men
   Likely to Refuse Locoregional Treatment for Prostate Adenocarcinoma Jessica
   Nye, PhD 23 July 2021 renalandurologynews.com A retrospective analysis of a
   cancer database identified which men were more likely to refuse locoregional
   treatment for… Obesity Linked to Lower Death Risk in mCRPC Jody A. Charnow 12
   July 2021 renalandurologynews.com Obesity in men with metastatic
   castration-resistant prostate cancer is associated with decreased risks for
   all-cause and… Fear of Recurrence Persists for Some Prostate Cancer Survivors
   Haymarket Media 1 September 2021 renalandurologynews.com
   
   Predictors include lower level of education, years since radical
   prostatectomy, FCR, no current adjuvant therapy, anxiety
   
   Many Men With Metastatic Prostate Cancer Die From Noncancer Causes Natasha
   Persaud 18 August 2021 medicalbag.com New findings may have implications for
   counseling patients with metastatic prostate cancer and highlight the
   importance …
 * 
 * Loading...
   
   Continuing Medical Education (CME/CE) Courses
   
   1,800 Seconds™ in The Expanding Role of PARP Inhibitors in Ovarian Cancer
   Haymarket Media 21 August 2021 mycme.com Stepwise Therapy in the Management
   of Atopic Dermatitis Haymarket Media 21 August 2021 mycme.com Precision
   Medicine in Non-Small Cell Lung Carcinoma: New Paradigms and Best Practices
   in Targeted Therapy Haymarket Media 21 August 2021 mycme.com Connective
   Tissue Disease and Pulmonary Arterial Hypertension: Multidisciplinary
   Coordination of Care to Optimize Outcomes Haymarket Media 21 August 2021
   mycme.com Improving Outcomes in CTD-PAH: Diagnosis, Treatment &
   Multidisciplinary Care Haymarket Media 21 August 2021 mycme.com OFF to ON:
   Strategies to Manage OFF Episodes in Patients with Parkinson’s disease
   Haymarket Media 21 August 2021 mycme.com
   
   Show More

 * 


WANT TO READ MORE?

Please login or register first to view this content.

Login Register


Open
Next post in Prostate Cancer Close


INTENSE NEOADJUVANT ADT MAY NOT IMPROVE POST-RP OUTCOMES IN HIGH-RISK PROSTATE
CANCER

Back to Top

 * Renal & Urology News publishes timely news coverage of scientific
   developments of interest to nephrologists and urologists, including in-depth
   coverage of all relevant medical conferences.
   
   All of the news and departments from the print edition are fully archived on
   the site.

 * 
 * 
 * 

 * RESOURCES
   
    * Editorial Board
    * Reprints/Permissions
    * Issue Archive

 * USER CENTER
   
    * About Us
    * Contact Us
    * Advertise
    * Ad Choices

 * OTHER HAYMARKET MEDICAL WEBSITES
   
    * Cancer Therapy Advisor
    * Clinical Advisor
    * Clinical Pain Advisor
    * Dermatology Advisor
    * Endocrinology Advisor
    * Gastroenterology Advisor
    * Hematology Advisor
    * Infectious Disease Advisor
    * McKnight’s Long Term Care News
    * McKnight’s Senior Living
    * Medical Bag
    * MPR
    * myCME
    * Neurology Advisor
    * Oncology Nurse Advisor
    * Ophthalmology Advisor
    * Psychiatry Advisor
    * Pulmonology Advisor
    * Rare Disease Advisor
    * Rheumatology Advisor
    * The Cardiology Advisor

 * Copyright © 2021 Haymarket Media, Inc. All Rights Reserved
   This material may not be published, broadcast, rewritten or redistributed in
   any form without prior authorization.
   Your use of this website constitutes acceptance of Haymarket Media’s Privacy
   Policy and Terms & Conditions.

Some areas of this page may shift around if you resize the browser window. Be
sure to check heading and document order.
Close more info about Active Surveillance for Intermediate-Risk Prostate Cancer
Linked With Lower Survival


LOG IN TO RENAL AND UROLOGY NEWS




PLEASE LOG IN USING YOUR PASSWORD.

*Required
Keep me signed in

Forgot your password?

Login

Do not have an account yet? Register


Close more info about Active Surveillance for Intermediate-Risk Prostate Cancer
Linked With Lower Survival


JOIN THE




CREATING YOUR FREE ACCOUNT WITH RENAL AND UROLOGY NEWS ALLOWS YOU ACCESS TO
EXCLUSIVE CONTENT, INCLUDING CASE STUDIES, DRUG INFORMATION, CME AND MORE ACROSS
OUR GROWING NETWORK OF CLINICAL SITES.

*Required
*ProfessionCertified Diabetes EducatorClinical Nurse SpecialistConsumer /
PatientDentistDietitian / NutritionistGenetic CounselorNurseNurse
PractitionerOther Healthcare ProfessionalPharmacistPhysicianPhysician
AssistantPsychologistResidentStudent

*SpecialtyAllergy / ImmunologyAnesthesiologyBariatric
MedicineCardiologyComplementary / Alternative MedicineCritical Care
MedicineDentalDermatologyDiabetesEmergency MedicineEndocrinologyFamily Medicine
/ General PracticeGastroenterology / ProctologyGeriatric
MedicineHematologyHematology / OncologyHospitalistInfectious DiseaseInfusion
TherapyInternal MedicineLong-Term CareNephrologyNeurologyNutritionObstetrics /
GynecologyOncologyOphthalmologyOptometryOrthopedicsOtolaryngologyPain
MedicinePathologyPediatricsPharmacyPhysical Medicine /
RehabilitationPsychiatryPublic Health / Preventive MedicinePulmonologyRadiology
/ Nuclear MedicineRheumatologySports MedicineSurgeryUrologyOther

*Select a CountryAfghanistanAlbaniaAlgeriaAmerican
SamoaAndorraAngolaAnguillaAntarcticaAntigua and
BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia
and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei
DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman
IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling)
IslandsColombiaComorosCongoCongo (DRC)Cook IslandsCosta
RicaCroatiaCubaCyprusCzech RepublicCôte D'IvoireDenmarkDjiboutiDominicaDominican
RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland
Islands (Malvinas)Faroe IslandsFiji IslandsFinlandFranceFrench GuianaFrench
PolynesiaFrench Southern
TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard
Island and Mcdonald IslandsHondurasHong
KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall
IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands
AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth
KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPanamaPapua New
GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto
RicoQatarReunionRomaniaRussiaRwandaSaint HelenaSaint Kitts and NevisSaint
LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and The GrenadinesSan
MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbia and
MontenegroSerbia-MontenegroSeychellesSierra
LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri
LankaSudanSurinameSvalbard and Jan
MayenSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad
and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos
IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited
StatesUruguayUzbekistanVanuatuVatican CityVenezuelaViet NamVirgin IslandsVirgin
Islands, BritishWallis and FutunaWestern SamoaYemenZambiaZimbabwe

--State--AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew
HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth
DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth
DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington, D.C.West
VirginiaWisconsinWyoming


REGISTER FOR EMAIL NEWSLETTERS

Today’s Update
Renal & Urology News eTOC
Register

Already have an account with one of our brands? LOG IN

Terms and Conditions | Privacy Policy


Close more info about Active Surveillance for Intermediate-Risk Prostate Cancer
Linked With Lower Survival

Close more info about Active Surveillance for Intermediate-Risk Prostate Cancer
Linked With Lower Survival


LOG IN TO RENAL AND UROLOGY NEWS




PLEASE LOG IN USING YOUR PASSWORD.

*Required
Keep me signed in

Forgot your password?

Login

Do not have an account yet? Register


Close more info about Active Surveillance for Intermediate-Risk Prostate Cancer
Linked With Lower Survival


JOIN THE




CREATING YOUR FREE ACCOUNT WITH RENAL AND UROLOGY NEWS ALLOWS YOU ACCESS TO
EXCLUSIVE CONTENT, INCLUDING CASE STUDIES, DRUG INFORMATION, CME AND MORE ACROSS
OUR GROWING NETWORK OF CLINICAL SITES.

*Required
*ProfessionCertified Diabetes EducatorClinical Nurse SpecialistConsumer /
PatientDentistDietitian / NutritionistGenetic CounselorNurseNurse
PractitionerOther Healthcare ProfessionalPharmacistPhysicianPhysician
AssistantPsychologistResidentStudent

*SpecialtyAllergy / ImmunologyAnesthesiologyBariatric
MedicineCardiologyComplementary / Alternative MedicineCritical Care
MedicineDentalDermatologyDiabetesEmergency MedicineEndocrinologyFamily Medicine
/ General PracticeGastroenterology / ProctologyGeriatric
MedicineHematologyHematology / OncologyHospitalistInfectious DiseaseInfusion
TherapyInternal MedicineLong-Term CareNephrologyNeurologyNutritionObstetrics /
GynecologyOncologyOphthalmologyOptometryOrthopedicsOtolaryngologyPain
MedicinePathologyPediatricsPharmacyPhysical Medicine /
RehabilitationPsychiatryPublic Health / Preventive MedicinePulmonologyRadiology
/ Nuclear MedicineRheumatologySports MedicineSurgeryUrologyOther

*Select a CountryAfghanistanAlbaniaAlgeriaAmerican
SamoaAndorraAngolaAnguillaAntarcticaAntigua and
BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia
and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei
DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman
IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling)
IslandsColombiaComorosCongoCongo (DRC)Cook IslandsCosta
RicaCroatiaCubaCyprusCzech RepublicCôte D'IvoireDenmarkDjiboutiDominicaDominican
RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland
Islands (Malvinas)Faroe IslandsFiji IslandsFinlandFranceFrench GuianaFrench
PolynesiaFrench Southern
TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard
Island and Mcdonald IslandsHondurasHong
KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall
IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands
AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth
KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPanamaPapua New
GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto
RicoQatarReunionRomaniaRussiaRwandaSaint HelenaSaint Kitts and NevisSaint
LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and The GrenadinesSan
MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbia and
MontenegroSerbia-MontenegroSeychellesSierra
LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri
LankaSudanSurinameSvalbard and Jan
MayenSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad
and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos
IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited
StatesUruguayUzbekistanVanuatuVatican CityVenezuelaViet NamVirgin IslandsVirgin
Islands, BritishWallis and FutunaWestern SamoaYemenZambiaZimbabwe

--State--AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew
HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth
DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth
DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington, D.C.West
VirginiaWisconsinWyoming


REGISTER FOR EMAIL NEWSLETTERS

Today’s Update
Renal & Urology News eTOC
Register

Already have an account with one of our brands? LOG IN

Terms and Conditions | Privacy Policy



Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest
clinical news, full-length features, case studies, and more.

You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If
you wish to read unlimited content, please log in or register below.
Registration is free.

{{login-button}} {{register-button}}

Log in to continue reading this article.

Don’t miss out on today’s top content on Renal & Urology News. Register for free
and gain unlimited access to:

- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More

{{login-button}} {{register-button}}


WANT TO READ MORE?

Please login or register first to view this content.

Login Register


x